Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy; CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia in patients for whom existing treatments are insufficient; and CAT-2003 that has completed Phase IIa trials to the treatment of patients with elevated triglycerides or hypertriglyceridemia. It is also developing CAT-4001 that is in preclinical stage for the treatment for severe, rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has a collaboration with dystrophy association for the development of CAT-1004, a treatment for duchenne muscular dystrophy. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is Cambridge, Massachusetts.
http://www.priceseries.com/trade/CATB-Catabasis-Pharmaceuticals-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2017092720171010.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments